(Q41089635)

26 September 2017

1 reference

title

Evolving role of sotalol in the management of ventricular tachyarrhythmias (English)

1 reference

26 September 2017

P A O'Callaghan

1

1 reference

26 September 2017

B A McGovern

series ordinal

2

1 reference

26 September 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

American Journal of Cardiology

26 September 2017

published in

1 reference

26 September 2017

volume

78

1 reference

26 September 2017

issue

4A

1 reference

26 September 2017

page(s)

54-60

1 reference

Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Comparative Antifibrillatory Effects of d- and dl-Sotalol in Normal and Ischaemic Ventricular Muscle of the Cat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

QT dispersion: an indication of arrhythmia risk in patients with long QT intervals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Reduction in QT dispersion by sotalol following myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Effects of amiodarone, sematilide, and sotalol on QT dispersion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Sotalol versus class I and II antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Relation between ventricular function and antiarrhythmic responses to sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Controlled trial of sotalol for one year after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Sotalol-induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

DL and D sotalol decrease defibrillation energy requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Effect of sotalol on ventricular fibrillation and defibrillation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

Clinical safety profile of sotalol in patients with arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2896%2900453-5

10.1016/S0002-9149(96)00453-5

7 January 2021

Identifiers

DOI

1 reference

26 September 2017

1 reference